FDA D.I.S.C.O. Burst Edition: FDA approval of Retevmo (selpercatinib) for advanced or metastatic RET fusion-positive thyroid cancer

On May 8, 2020, ceprtinib became the first prescription drug targeting RET protein to be approved by the U.S. Food and Drug Administration (FDA). Please follow your doctor's instructions.

On May 8, 2020, the U.S. Food and Drug Administration (FDA) approved selpercatinib, the first drug approved specifically for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) that is positive for transfected rearranged gene (RET) fusions, and adult patients and children aged 12 years and older with advanced or metastatic medullary thyroid carcinoma harboring RET mutations who require systemic therapy, as well as adult patients and children aged 12 years and older with RET fusion-positive advanced or metastatic thyroid cancer that are refractory to systemic therapy and radioactive iodine therapy (if applicable).